1h Free Analyst Time
The publisher has been monitoring the anti-venom market and it is poised to grow by $481.51 mn during 2022-2026, progressing at a CAGR of 7.82% during the forecast period. The report on the anti-venom market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the rising prevalence of venomous bites and stings and increasing awareness about anti-venoms.
The anti-venom market analysis includes the type segment and geographic landscape.
The anti-venom market is segmented as below:
By Type
- Polyvalent anti-venom
- Monovalent anti-venom
- Other anti-venom types
By Geographical Landscape
- North America
- Asia
- Europe
- ROW
This study identifies the rising R&D for anti-venoms as one of the prime reasons driving the anti-venom market growth during the next few years.
The report on anti-venom market covers the following areas:
- Anti-venom market sizing
- Anti-venom market forecast
- Anti-venom market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading anti-venom market vendors that include Bharat Serums and Vaccines Ltd., Boehringer Ingelheim International GmbH, CSL Ltd., Haffkine bio pharmaceutical Corp. Ltd., Merck KGaA, Pfizer Inc., Rare Disease Therapeutics Inc., SERB Sarl, Serum Institute of India Pvt. Ltd., and VINS Bioproducts Ltd. Also, the anti-venom market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Table of Contents
Executive Summary- Market Overview
Market Landscape
- Market ecosystem
- Value chain analysis
Market Sizing
- Market definition
- Market segment analysis
- Market size 2021
- Market outlook: Forecast for 2021 - 2026
Five Forces Analysis
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
Market Segmentation by Type
- Market segments
- Comparison by Type
- Polyvalent anti-venom - Market size and forecast 2021-2026
- Monovalent anti-venom - Market size and forecast 2021-2026
- Other anti-venom types - Market size and forecast 2021-2026
- Market opportunity by Type
Geographic Landscape
- Geographic segmentation
- Geographic comparison
- North America - Market size and forecast 2021-2026
- Asia - Market size and forecast 2021-2026
- Europe - Market size and forecast 2021-2026
- ROW - Market size and forecast 2021-2026
- Key leading countries
- Market opportunity By Geographical Landscape
- Market drivers
- Market challenges
- Market trends
Vendor Landscape
- Landscape disruption
Vendor Analysis
- Vendors covered
- Market positioning of vendors
- Bharat Serums and Vaccines Ltd.
- Boehringer Ingelheim International GmbH
- CSL Ltd.
- Merck KGaA
- Pfizer Inc.
- Rare Disease Therapeutics Inc.
- SERB Sarl
- Serum Institute of India Pvt. Ltd.
- VINS Bioproducts Ltd.
Appendix
- Scope of the report
- Currency conversion rates for US$
- Research methodology
- List of abbreviations
List of Exhibits
- Key Finding 1
- Key Finding 2
- Key Finding 3
- Key Finding 5
- Key Finding 6
- Key Finding 7
- Key Finding 8
- Parent market
- Market characteristics
- Offerings of vendors included in the market definition
- Market segments
- Global - Market size and forecast 2021 - 2026 ($ million)
- Global market: Year-over-year growth 2021 - 2026 (%)
- Five forces analysis 2021 & 2026
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition - Five forces 2021
- Type - Market share 2021-2026 (%)
- Comparison by Type
- Polyvalent anti-venom - Market size and forecast 2021-2026 ($ million)
- Polyvalent anti-venom - Year-over-year growth 2021-2026 (%)
- Monovalent anti-venom - Market size and forecast 2021-2026 ($ million)
- Monovalent anti-venom - Year-over-year growth 2021-2026 (%)
- Other anti-venom types - Market size and forecast 2021-2026 ($ million)
- Other anti-venom types - Year-over-year growth 2021-2026 (%)
- Market opportunity by Type
- Customer landscape
- Market share By Geographical Landscape 2021-2026 (%)
- Geographic comparison
- North America - Market size and forecast 2021-2026 ($ million)
- North America - Year-over-year growth 2021-2026 (%)
- Asia - Market size and forecast 2021-2026 ($ million)
- Asia - Year-over-year growth 2021-2026 (%)
- Europe - Market size and forecast 2021-2026 ($ million)
- Europe - Year-over-year growth 2021-2026 (%)
- ROW - Market size and forecast 2021-2026 ($ million)
- ROW - Year-over-year growth 2021-2026 (%)
- Key leading countries
- Market opportunity By Geographical Landscape ($ million)
- Impact of drivers and challenges
- Vendor landscape
- Landscape disruption
- Industry risks
- Vendors covered
- Market positioning of vendors
- Bharat Serums and Vaccines Ltd. - Overview
- Bharat Serums and Vaccines Ltd. - Business segments
- Bharat Serums and Vaccines Ltd. - Key offerings
- Bharat Serums and Vaccines Ltd. - Key customers
- Bharat Serums and Vaccines Ltd. - Segment focus
- Boehringer Ingelheim International GmbH - Overview
- Boehringer Ingelheim International GmbH - Business segments
- Boehringer Ingelheim International GmbH - Key offerings
- Boehringer Ingelheim International GmbH - Key customers
- Boehringer Ingelheim International GmbH - Segment focus
- CSL Ltd. - Overview
- CSL Ltd. - Business segments
- CSL Ltd. - Key offerings
- CSL Ltd. - Key customers
- CSL Ltd. - Segment focus
- Haffkine bio pharmaceutical Corp. Ltd. - Overview
- Haffkine bio pharmaceutical Corp. Ltd. - Product and service
- Haffkine bio pharmaceutical Corp. Ltd. - Key offerings
- Haffkine bio pharmaceutical Corp. Ltd. - Key customers
- Haffkine bio pharmaceutical Corp. Ltd. - Segment focus
- Merck KGaA - Overview
- Merck KGaA - Business segments
- Merck KGaA - Key offerings
- Merck KGaA - Key customers
- Merck KGaA - Segment focus
- Pfizer Inc. - Overview
- Pfizer Inc. - Business segments
- Pfizer Inc. - Key offerings
- Pfizer Inc. - Key customers
- Pfizer Inc. - Segment focus
- Rare Disease Therapeutics Inc. - Overview
- Rare Disease Therapeutics Inc. - Product and service
- Rare Disease Therapeutics Inc. - Key offerings
- Rare Disease Therapeutics Inc. - Key customers
- Rare Disease Therapeutics Inc. - Segment focus
- SERB Sarl - Overview
- SERB Sarl - Product and service
- SERB Sarl - Key offerings
- SERB Sarl - Key customers
- SERB Sarl - Segment focus
- Serum Institute of India Pvt. Ltd. - Overview
- Serum Institute of India Pvt. Ltd. - Product and service
- Serum Institute of India Pvt. Ltd. - Key offerings
- Serum Institute of India Pvt. Ltd. - Key customers
- Serum Institute of India Pvt. Ltd. - Segment focus
- VINS Bioproducts Ltd. - Overview
- VINS Bioproducts Ltd. - Product and service
- VINS Bioproducts Ltd. - Key offerings
- VINS Bioproducts Ltd. - Key customers
- VINS Bioproducts Ltd. - Segment focus
- Currency conversion rates for US$
- Research Methodology
- Validation techniques employed for market sizing
- Information sources
- List of abbreviations
Executive Summary
The publisher recognizes the following companies as the key players in the global anti-venom market: Bharat Serums and Vaccines Ltd., Boehringer Ingelheim International GmbH, CSL Ltd., Haffkine bio pharmaceutical Corp. Ltd., Merck KGaA, Pfizer Inc., Rare Disease Therapeutics Inc., SERB Sarl, Serum Institute of India Pvt. Ltd., and VINS Bioproducts Ltd.Commenting on the report, an analyst from the research team said: `The latest trend gaining momentum in the market is rising R&D for anti-venoms.`
According to the report, one of the major drivers for this market is the rising prevalence of venomous bites and stings.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Bharat Serums and Vaccines Ltd.
- Boehringer Ingelheim International GmbH
- CSL Ltd.
- Haffkine bio pharmaceutical Corp. Ltd.
- Merck KGaA
- Pfizer Inc.
- Rare Disease Therapeutics Inc.
- SERB Sarl
- Serum Institute of India Pvt. Ltd.
- VINS Bioproducts Ltd.
